December 15, 2022 03:53 PM ESTUpdated 04:35 PM
R&D

De­bat­ing the p-val­ues be­hind Mod­er­na's $16B mar­ket-cap gain

Jared Whitlock

Features Editor

On Tues­day, Mod­er­na and Mer­ck re­port­ed what looked like one of the most ex­cit­ing pieces of bio­phar­ma news of the year: Mod­er­na’s mR­NA vac­cine …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times